SCHEMBL770215

SCHEMBL770215

COC(=O)CCSC(=O)N1CCCC2CCCC=C21

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 2/20 0.32
ALDH1A1 P00352 3/20 0.31
KMT2A Q03164 3/20 0.31
MEN1 O00255 2/20 0.31
FAAH O00519 1/20 0.31
MGLL Q99685 1/20 0.31
KDM4E B2RXH2 4/20 0.31
MAPT P10636 3/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
GAA P10253 1/20 0.31
PPP1CA P62136 1/20 0.31
NOTUM Q6P988 1/20 0.30
OPRD1 P41143 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770583 0.85
SCHEMBL771018 0.81 ALDH1A1 (0.40) HRH3SMN1; SMN2POLBALDH1A1KMT2A
SCHEMBL770357 0.80 EPHX2 (0.39) HRH3SMN1; SMN2POLBALDH1A1KMT2A
SCHEMBL770193 0.78 EPHX2 (0.41) HRH3SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL772365 0.77 PDE4B (0.34) HRH3POLBALDH1A1KMT2AMEN1
SCHEMBL770035 0.76 FAAH (0.40) SMN1; SMN2ALDH1A1KMT2AFAAHMGLL
SCHEMBL771484 0.73 LMNA (0.30) LMNA
SCHEMBL771465 0.73 LMNA (0.41) SMN1; SMN2LMNA
SCHEMBL770345 0.72 SMYD3 (0.37) HRH3SMN1; SMN2POLBALDH1A1KMT2A
SCHEMBL770581 0.72 ALOX15 (0.37) HRH3SMN1; SMN2POLBALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HRH3 1687/4885SMN1; SMN2 3653/4885POLB 375/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HRH3 1698/4885SMN1; SMN2 3637/4885POLB 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.